Eleven Biotherapeutics (NASDAQ: EBIO) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Eleven Biotherapeutics to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.
Volatility & Risk
Eleven Biotherapeutics has a beta of 3.49, indicating that its stock price is 249% more volatile than the S&P 500. Comparatively, Eleven Biotherapeutics’ competitors have a beta of 6.62, indicating that their average stock price is 562% more volatile than the S&P 500.
Institutional & Insider Ownership
5.0% of Eleven Biotherapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.0% of Eleven Biotherapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Eleven Biotherapeutics and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Eleven Biotherapeutics||$29.90 million||$9.65 million||5.14|
|Eleven Biotherapeutics Competitors||$260.16 million||$66.28 million||-6.28|
Eleven Biotherapeutics’ competitors have higher revenue and earnings than Eleven Biotherapeutics. Eleven Biotherapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and target prices for Eleven Biotherapeutics and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Eleven Biotherapeutics Competitors||765||3040||11221||227||2.72|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.14%. Given Eleven Biotherapeutics’ competitors higher possible upside, analysts clearly believe Eleven Biotherapeutics has less favorable growth aspects than its competitors.
This table compares Eleven Biotherapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Eleven Biotherapeutics Competitors||-5,489.25%||-451.68%||-42.65%|
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).
What are top analysts saying about Eleven Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eleven Biotherapeutics Inc. and related companies.